ArticleVirchows Archiv : an international journal of pathology2025
PD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure".Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Genomic imbalance at 9p24.1 locus, the chromosome region that maps PD-L1 and PD-L-2 (programmed death ligand 1 and 2) genes, is a recurrent alteration in classic Hodgkin lymphoma (cHL). We analyzed 9p24.1 imbalance by fluorescence in situ hybridization assay on formalin-fixed paraffin-embedded biopsies of 28 patients with newly diagnosed cHL to characterize the genetic profiles. Results were correlated with PD-L1 (H-score) and LMP-1 (latent membrane protein 1) protein expression of Epstein-Barr virus by immunohistochemistry and clinical features. Genomic alterations in Hodgkin/Reed Sternberg (H/RS) cells were classified as amplification, copy gain, and polysomy. Three molecular cytogenetic groups were defined according to the type and frequency of the copy number alteration: Group A (with amplification) 32%, Group G (with > 50% cells with copy gains but without amplification) 36%, and Group P (with ≥ 50% cells with polysomies but without amplification) 32%. A different frequency of copy gains (p = 0.02) and polysomies (p ≤ 0.01) among groups was found. A negative correlation between the percentage of H/RS cells with polysomies and the PD-L1 protein expression (p ≤ 0.01) was observed. Tumor microenvironmental cells showed chromosome 9 monosomy particularly associated to Group P. The highest H-score mean value was observed in Group A (265.6), while Groups G and P showed 123 and 60.3 H-score, respectively. Group P showed the highest mean age (p = 0.036) and increased frequency of advanced stages, B symptoms, and extranodal involvement, while Groups A and G were associated with localized stages (p = 0.035) and bulky mass, highlighting the importance of 9p24.1 genomic imbalance profile in the biological characterization of cHL.
Indexed as
Identifiers
39976683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.